RWG
SONN

Ratio Wealth Group’s Sonnet BioTherapeutics SONN Stock Holding History

Ratio Wealth Group’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9
Closed -$6.3K – 63
2022
Q2 		$6.3K Hold
9
– – ﹤0.01% 57
2022
Q1 		$8.46K Buy
+9
New +$7.61K ﹤0.01% 57

Other funds holding SONN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ratio Wealth Group's SONN Position: Q3 2022 in Review

Ratio Wealth Group sold out of Sonnet BioTherapeutics (SONN) in Q3 2022, closing a stake of 9 shares — an estimated $6.3K sold.

Ratio Wealth Group first reported a position in SONN in Q1 2022 and held it in 2 quarters. The position peaked at $8.46K in Q1 2022. 10 funds tracked by Wall St. Rank hold SONN as of Q3 2022.

  • Ratio Wealth Group reported no remaining Sonnet BioTherapeutics position as of Q3 2022 after selling out during the quarter.
  • Ratio Wealth Group sold 9 Sonnet BioTherapeutics shares in Q3 2022, an estimated $6.3K.
  • Ratio Wealth Group first reported a position in Sonnet BioTherapeutics in Q1 2022 and held it in 2 quarters.
  • Ratio Wealth Group's Sonnet BioTherapeutics position peaked at $8.46K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2022.

Based on Ratio Wealth Group's 13F filing for Q3 2022, filed 27 Mar 2023.